Group items tagged

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIBIB R25 program is to support educational activities that include innovative approaches to enhance biomedical engineering design education to ensure a future workforce that can meet the nations needs in biomedical research and healthcare technologies. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. This FOA encourages applications from institutions that propose to establish new or to enhance existing team-based design courses or programs in undergraduate biomedical engineering departments or other degree-granting programs with biomedical engineering tracks/minors. This FOA targets undergraduate students. While current best practices such as multidisciplinary/interdisciplinary education, introduction to the regulatory pathway and other issues related to the commercialization of medical devices, and clinical immersion remain encouraged components of a strong BME program, this FOA also challenges institutions to propose other novel, innovative and/or ground-breaking activities that can form the basis of the next generation of biomedical engineering design education.

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) and VentureWell have come together to support and expand DEBUT, a competition that recognizes undergraduate excellence in biomedical design and innovation. DEBUT challenges teams of students in undergraduate biomedical education to solve real-world problems in healthcare. Prizes of up to $20,000 will be awarded. Strong DEBUT submissions will demonstrate a mastery of analytical and design skills and capabilities; the ability to manage the product development process; the ability to work effectively in teams; and technical communication skills. Submissions will be judged on the following criteria: Significance of the problem being addressed Impact of the proposed solution on potential users and clinical care Innovative design Working prototype Additional prizes will be awarded to entries that also demonstrate: Market potential and economic feasibility Patentability

This Funding Opportunity Announcement (FOA) is a new initiative to support the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs).  Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost devices or assays that are clinically comparable to currently used technologies for imaging, in vitro detection/diagnosis, or treatment of cancers in humans living in LMICs. Funds will be made available through the UH2/UH3 phased innovation cooperative agreement award mechanism.  Applicants should have a working assay or prototype (not necessarily already capable of cancer applications).  The initial 2-year (or shorter) UH2 exploratory phase will be a feasibility study to demonstrate technical functionality and clinical potential for use in LMIC settings by meeting specific performance milestones.  UH2 projects that have met their milestones will be administratively considered by NCI and prioritized for transition to the UH3 validation phase.  UH3 awards will support improvements and validations of the technologies in the LMIC settings.  The project period for the UH3 phase is up to 3 years.  Projects proposed in response to this FOA will require multidisciplinary efforts to succeed and therefore all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development.  Investigators responding to this FOA must address both UH2 and UH3 phases.

A major objective of this funding opportunity announcement (FOA) is to invite SBIR applications to foster collaboration between clinical and bioengineering research communities to develop and test safe, accurate, and effective devices for use in neonatal, perinatal, and pediatric care settings. These can be new devices or improvements on existing devices. The studies may range from concept to developmental phases, with a clear commercialization plan to enable healthcare providers to use them in regular clinical care settings in the population, which is the focus of this FOA.

The Muscular Dystrophy Association is the world's leading nonprofit health agency dedicated to finding treatments and cures for muscular dystrophy, amyotrophic lateral sclerosis (ALS), and other neuromuscular diseases. It advances this mission by funding research; providing comprehensive healthcare services and support to MDA families nationwide; and rallying communities to fight back through advocacy, fundraising, and local engagement.

The purpose of the Funding Opportunity Announcement (FOA) is to promote the assessment and further development of simulation technologies intended to improve patient safety and healthcare outcomes provided by practicing patient care providers and experienced (not trainee) physicians. The FOA seeks applications directed toward three areas of research: 1) Skill Acquisition: to evaluate strategies and protocols for simulation-based methods for skill acquisition and maintenance by experienced clinicians; 2) Outcomes Assessment: to assess the relationship of simulation-based assessments of skills demonstrated by experienced clinicians with the quality of clinical care delivered by those clinicians, and to identify strategies to increase the quality of simulation-based assessments of skills; and 3) Technology Development: to develop virtual coaches by incorporating intelligent technologies into existing simulators to provide adaptive, cognitive assistance to coach experienced practitioners in retaining, retraining and improving performance levels in the context of the user environment (and physiological system as appropriate).

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) and VentureWell have come together to support and expand DEBUT, a competition that recognizes undergraduate excellence in biomedical design and innovation. DEBUT challenges teams of students in undergraduate biomedical education to solve real world problems in healthcare. Prizes of up to $20,000 will be awarded, with a total prize purse of $80,000. Strong DEBUT submissions will demonstrate a mastery of analytical and design skills and capabilities; the ability to manage the product development process; the ability to work effectively in teams; and technical communication skills. Submissions will be judged on the following criteria: Significance of the problem being addressed Impact of proposed solution on potential users and clinical care Innovative design Working prototype

Pharmaceutical company AmerisourceBergen created the AmerisourceBergen Foundation as a separate not-for-profit charitable organization with the aim of supporting health and education-related causes that enrich the lives of its global community. To accomplish that goal, the foundation provides funding for programs and organizations focused on expanding access to quality healthcare - both human and animal - around the world. In the view of the foundation, the current epidemic of opioid abuse and misuse is a crisis that demands attention, action, and accountability. Understanding the need for expediency, the foundation is inviting grant-funded nonprofit organizations to submit proposals that describe how it can best contribute resources and funding to address opioid abuse and misuse. Grants will be awarded for the most innovative and constructive solutions in one of two key areas of focus: safe disposal and education around prevention. Applicants are strongly encouraged to identify and leverage existing, proven, evidence-based frameworks and strategies, as well as existing tools and materials, but may also propose original and innovative projects. Applications focused on education may address a spectrum of needs, but priority will be given to the effective dissemination of the following topics: provider education about appropriate opioid prescribing; patient education about the risks and effects of prescription opioids, and what to do if they have concerns about addiction; public education, especially aimed at rural communities; training to reduce youth risk factors (such as delinquency) and boost protective factors (such as decision-making skills for problem solving and resisting peer pressure; addiction as a childhood onset condition; preventing teens from initiating problematic opioid use in the first place; and advising parents of teens to lock up prescription opioid medications and dispose of old pills.

The purpose of this Notice of Funding Opportunity (NOFO) is to support the applicant's management of domestic fellowships for students or recent graduates of CEPH-accredited schools or programs of public health or CCNE-accredited baccalaureate and higher degree colleges of nursing. Fellowships and other similar experiential placements are vital to CDC's strategic interests to ensure students and emerging health professionals receive adequate hand-on experience in public health practice at CDC's domestic offices, at state, tribal, local, and territorial health departments, and at other community-based settings. For the purposes of this NOFO, fellowships are for recent graduates within five years of graduation. The overall goal is to create the opportunities for academia to develop qualified, knowledgeable and experienced students and emerging health professionals suitably prepared to serve in governmental public health practice, or able to apply public health concepts in various healthcare or other settings, to collectively meet the challenge of improving the population’s health. An application that exceeds the upper value of the specified dollar range will be considered non-responsive and will not receive further review.

The American Cancer Society is accepting proposals for research projects with the potential to generate new knowledge of the effects of the United States healthcare system structure and the role of insurance in both access to and the outcomes of cancer screening, early detection, and treatment services. ACS is keenly interested in supporting rapid learning research on the effects of health policy changes on patients, providers, and health systems. This includes but is not limited to facilitators and barriers to care; unintended consequences; differential experiences and outcomes of patients seeking or receiving care; best practice models for quality care; and economic impact. Awards will not exceed $200,000 per year (direct costs) for up to four years. To be eligible, applicants must be affiliated with a nonprofit institution in the United States, one of its territories, or the Commonwealth of Puerto Rico; and be a U.S. citizen, non-citizen national, or permanent resident of the United States. Independent investigators at all stages of their career are encouraged to apply.

In 2015, NEA adopted a comprehensive strategic plan, the Roadmap to Advocacy, after extensive discussions with industry, patients, parents, and provider stakeholders. This plan places significant emphasis on understanding the overall burden of atopic dermatitis (AD), including the impact AD has on patients, families, the healthcare system, places of school and work, and society as a whole. NEA aims to become a steward of burden of disease research by serving as a clearinghouse for patient-centered data that can be readily shared with individuals and organizations interested in improving the lives of patients with eczema. NEA will ultimately utilize research on the burden of AD to further our mission to improve the health and quality of life for individuals with AD.

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) and VentureWell hold the Design by Biomedical Undergraduate Teams (DEBUT) Challenge which recognizes undergraduate excellence in biomedical innovation. DEBUT will award a total of $100K to undergraduate student teams working on innovative solutions to unmet health and clinical problems. Revised Criteria for 2020 In light of the social distancing measures that kept most students from entering labs this year, we are modifying our criteria to acknowledge teams that had excellent ideas for healthcare innovations but could not build and/or test/debug a prototype. We also want to reward teams who were able to achieve a working prototype. For 2020, each team will receive an ideation score and a prototype score and the team's final score will be the higher of the two.

CurePSP, a nonprofit research and grantmaking organization, works to increase awareness of progressive supranuclear palsy, corticobasal degeneration, and other atypical Parkinsonian disorders; fund research toward treatment, cure and prevention; educate healthcare professionals; and provide support, information, and hope for affected persons and their families. To that end, the organization is accepting applications for student fellowships for research on progressive supranuclear palsy.

 The purpose of this limited competition Funding Opportunity Announcement (FOA) is to solicit the Center for International Blood and Marrow Transplant Research (CIBMTR) a limited competition application for the continued support of the Data Resource for Analyzing Blood and Marrow Transplants program. The support for this FOA is to ensure the continued availability of the CIBMTR database as a resource to investigators, transplant physicians, and healthcare policy-makers.

The key element of the national HIV/AIDS program is ART scale up contributing towards strategic goals of treatment cascade. This project will build on the successful creation of a HIV medical information system through the ACCESS project by scaling up implementation of the MIS to treatment sites in all 12 PEPFAR focus oblasts, including capacity building of healthcare workers, improving information management, analysis and use. The project will also develop and implement a laboratory information system module. In addition, the project will work with the treatment sites to implement quality improvement and facility index testing activities in coordination with other PEPFAR and Global Fund supported activities. The major expected project results are 1) functional HIV MIS is operated by a GOU affiliated Operator at treatment sites in the 12 PEPFAR priority regions and Vinnitsa; 2) MIS data used by sites, GoU, PEPFAR , and other stakeholders; 3) laboratory module implemented; 3) quality improvement activities are implemented at all supported treatment sites; 4) high coverage facility index testing is performed at supported sites.

This Funding Opportunity Announcement (FOA) seeks to promote the development of HIV interventions which target opportunities to improve the delivery of healthcare across the continuum of care for persons infected with HIV.

The FY17 HRRP TRA mechanism is being offered in this first year of the program to support preclinical translational research that will accelerate the movement of promising initiatives relevant to hearing restoration into clinical applications. The ultimate goal of translational research is to move an observation forward into clinical application and accelerate the clinical introduction of healthcare products, technologies, or practice guidelines. Observations that drive a research idea may be derived from a laboratory discovery, population-based studies, or a clinician's first-hand knowledge of patients and anecdotal data. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan should involve a reciprocal flow of ideas and information between basic and clinical science.

This Funding Opportunity Announcement (FOA) encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, cervical, colorectal, or lung cancers. Improving follow-up to abnormal screening tests is dependent on factors at the patient, provider, clinical team, clinic, healthcare institution, or community setting levels. Appropriate applications for this FOA should propose to intervene at two or more levels, and measure outcomes at three or more levels, while accounting for interactions that occur between and across levels.

Supported by the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH), EMF is inviting applications for its EMF/NIDA Mentor-Facilitated Training Award in Substance Use Disorders Science Dissemination. The award seeks works that addresses the overarching goals of EMF, including the promotion of knowledge of evidence-based SUD treatment among healthcare providers; the dissemination of substance use disorder research finding; the adoption of evidence-based approaches in medical settings, and the facilitation of the academic growth and development of future leaders in SUD management.

We encourage innovators to submit potentially ground-breaking ideas in perinatal care, including a particular interest in the following areas:  - Consumer Healthcare  - Community Health Approaches - Health Technologies  - Medical Devices  - Patient Care - Pharmaceuticals - Cross-sector Initiatives   Priority will be given to science-based potential innovations backed by data.  Applications that clearly describe a concept or path forward to achieve these goals will also be considered during evaluation. Please keep in mind that no idea is too big or too early for consideration. The goal of the Maternal Health QuickFire Challenge is to discover solutions aimed to help mothers survive and prevent adverse consequences from pregnancy and childbirth.  These potential solutions should be meet the below outlined criteria. The submitted potential solution must be either be pioneering or evidence based. Please provide data supporting the theory of change or the intervention accordingly. Submitted ideas must meet at least three of the below criteria: - Actionable - is the project achievable? - Measurable in terms of health impact - Filling a current data gap - Proven sustainability or strong rationale for a sustainable business model - Scalable